This disparity stems from their distinct mechanisms of action: EGFR antibodies effectively target EGFR overexpression regardless of mutational status, a characteristic feature of colorectal cancers [[90], [91], [92]]. The gene discussed is EGFR; the disease is colorectal cancer.